PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

NCT06345599 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

RADIATION: Radiotherapy
DRUG: Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab
DRUG: Chemotherapy:Albumin-bound paclitaxel、Gemcitabine

Sponsor

Second Affiliated Hospital of Soochow University